Haemonetics Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 28, 2026	Mar '25 Mar 29, 2025	Mar '24 Mar 30, 2024	Apr '23 Apr 1, 2023	Apr '22 Apr 2, 2022
Revenue	1,334	1,361	1,309	1,169	993.2
Revenue Growth (YoY)	-1.97%	3.95%	12.01%	17.67%	14.10%
Cost of Revenue	546.44	611.87	617.51	553.56	487.69
Gross Profit	787.59	748.96	691.55	615.1	505.5
Selling, General & Admin	442.42	436.79	429.78	376.68	340.14
Depreciation & Amortization Expenses	44	48.26	32.03	32.64	47.41
Research & Development	59.77	62.72	54.44	50.13	46.8
Other Operating Expenses	84.67	-20.63	10.42	-0.38	-9.6
Total Operating Expenses	630.85	527.14	526.67	459.06	424.75
Operating Income	156.73	221.82	164.88	156.03	80.75
Total Non-Operating Income (Expense)	-28.7	-9.75	-13.02	-14.63	-17.12
Pretax Income	128.03	212.07	151.87	141.4	63.63
Provision for Income Taxes	30.72	44.39	34.31	26	20.25
Net Income	97.31	167.68	117.56	115.4	43.38
Net Income to Common	97.31	167.68	117.56	115.4	43.38
Net Income Growth	-41.97%	42.63%	1.87%	166.05%	-45.42%
Shares Outstanding (Basic)	47	50	51	51	51
Shares Outstanding (Diluted)	47	51	51	51	51
Shares Change (YoY)	-6.65%	-1.30%	-0.04%	0.13%	0.12%
EPS (Basic)	2.06	3.33	2.32	2.27	0.85
EPS (Diluted)	2.05	3.31	2.29	2.24	0.84
EPS Growth	-38.07%	44.54%	2.23%	166.67%	-45.81%
Free Cash Flow	260.44	142.45	143.63	81.73	75.75
Free Cash Flow Growth	82.83%	-0.82%	75.73%	7.89%	5.56%
Free Cash Flow Per Share	5.50	2.81	2.79	1.59	1.48
Gross Margin	59.04%	55.04%	52.83%	52.63%	50.90%
Operating Margin	11.75%	16.30%	12.60%	13.35%	8.13%
Profit Margin	7.29%	12.32%	8.98%	9.87%	4.37%
FCF Margin	19.52%	10.47%	10.97%	6.99%	7.63%
EBITDA	268.45	337.4	262.1	249.34	178.5
EBITDA Margin	20.12%	24.79%	20.02%	21.34%	17.97%
EBIT	156.73	221.82	164.88	156.03	80.75
EBIT Margin	11.75%	16.30%	12.60%	13.35%	8.13%
Effective Tax Rate	24.00%	20.93%	22.59%	18.39%	31.83%

SEC Filings: 10-K · 10-Q